市场调查报告书
商品编码
1630515
全球近距离放射治疗市场:以产品类型(高剂量率与低剂量率)、技术、适应症、最终用户和地区预测 2032 年Brachytherapy Market Research Report Information, By Product, By Type (High Dose-Rate Brachytherapy, Low Dose-Rate Brachytherapy), By Technique, By Indication, By End-Users And By Region Industry Forecast Till 2032 |
全球近距离放射治疗市场规模预计将从2023 年的9.8 亿美元成长到2024 年的10.7 亿美元,预测期内的复合年增长率为6.84%,到2032 年将达到10.7 亿美元。到2032 年将成长至 2020 年将达到 19.4 亿美元。
近距离放射治疗的引入显着加速了近距离放射治疗市场的成长,因为它为癌症患者提供了更多的治疗选择。随着越来越多的患者寻求比传统放射疗法更有效的替代疗法,医疗机构正在扩大其服务范围,包括这种有针对性的微创技术。近距离放射治疗将目标剂量的放射线直接传送到恶性肿瘤,同时保护健康组织,进而改善患者的治疗效果和满意度。
此外,更短的治疗时间和更少的副作用已得到患者和医疗保健提供者的更多接受。 2024 年 9 月,印度卡纳塔克邦医学院和研究所引入了近距离放射治疗,这是子宫颈癌和食道癌治疗的重大进展。
区域展望
2023 年,北美将占据最大的市场占有率。此外,预计亚太地区在预测期内将呈现最高成长,复合年增长率为 7.98%。
北美市场的成长代表着癌症治疗策略的重大突破。随着局部癌症,尤其是子宫颈癌、乳癌和摄护腺癌的增加,对有效治疗的需求日益增长。
受多种因素影响,亚太市场正快速扩张。癌症,尤其是乳癌、摄护腺癌和子宫颈癌发生率的显着上升,促使对有效替代治疗方法的需求增加。
本报告研究了全球近距离放射治疗市场,提供了市场定义和概述、影响市场成长的各种因素的分析、市场规模的趋势和预测,以及各个细分市场、地区/区域的市场信息。
Brachytherapy Market Research Report Information, By Product (Afterloaders & Applicators, Radioactive Seeds, Electronic Brachytherapy, Imaging Systems, and Others), By Type (High Dose-Rate (HDR) Brachytherapy, Low Dose-Rate (LDR) Brachytherapy), By Technique (Interstitial Brachytherapy, Intracavitary Brachytherapy), By Indication (Prostate Cancer, Breast Cancer, Cervical Cancer, Skin Cancer, and Others), By End-Users (Hospitals & Specialty Clinics, Cancer Treatment Centers, and Others) And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) Industry Forecast Till 2032
In 2023, the brachytherapy market was estimated to be worth USD 0.98 billion. With a compound annual growth rate (CAGR) of 6.84% from 2024 to 2032, the sector is expected to increase from USD 1.07 billion in 2024 to USD 1.94 billion by 2032. The global rise in cancer cases and the number of new product launches are fueling the market's expansion.
By giving cancer patients more treatment alternatives, the introduction of brachytherapy services is greatly accelerating the growth of the brachytherapy market. More patients looking for efficient substitutes for conventional radiation therapy are drawn to healthcare facilities as they broaden their offers to include this focused, minimally invasive technique. Brachytherapy is improving patient outcomes and satisfaction by directly delivering focused radiation doses to malignancies while protecting healthy tissue.
Furthermore, patients' and healthcare providers' acceptance is being aided by shorter treatment durations and fewer adverse effects. An important development in the treatment of cervical and esophageal cancers was the introduction of brachytherapy services by Karnataka Medical College and Research Institute (India) in September 2024.
Perspectives on Market Segments
Afterloaders & Applicators, Radioactive Seeds, Electronic Brachytherapy, Imaging Systems, and Others are the product-based divisions of the Brachytherapy market.
The market has been divided into two segments based on type: low dose-rate (LDR) brachytherapy and high dose-rate (HDR) brachytherapy.
The brachytherapy market has been divided into two segments based on technique: intracavity brachytherapy and interstitial brachytherapy.
The market has been divided into several segments based on indications, including skin cancer, breast cancer, prostate cancer, and cervical cancer.
The market for brachytherapy has been divided into three segments based on end users: cancer treatment centers, hospitals and specialty clinics, and others.
Regional Perspectives
The market for brachytherapy has been divided into four regions: North America, Europe, Asia-Pacific, and the Rest of the World. In 2023, North America held the biggest market share. Nonetheless, over the course of the forecast period, Asia-Pacific is anticipated to develop at the highest CAGR of 7.98%.
The market for brachytherapy is expanding quickly in North America, which is indicative of major developments in cancer treatment strategies. The need for efficient treatments has increased as cancer rates grow, especially for localized types including cervical, breast, and prostate cancers.
The market for brachytherapy in Asia-Pacific is expanding rapidly due to a number of interconnected factors. The need for efficient treatment alternatives has increased due to a notable rise in the incidence of cancer, especially breast, prostate, and cervical malignancies.
In addition, the rest of the world is further separated into South America, Africa, and the Middle East. The region's economic growth has raised healthcare expenditures, improving access to cutting-edge cancer treatment alternatives.
Siemens Healthineers AG, Elekta, BEBIG Medical Gmbh, Becton, Dickinson and Company (US), GE Healthcare (US), Merit Medical Systems (US), Best Medical International, Inc. (US), IsoAid, LLC (US), Theragenics Corporation, Eckert & Ziegler, and others are major competitors in the brachytherapy market.